Predictive in vitro test methods addressing the parameters relevant to drug release in the
pediatric gastrointestinal tract could be an appropriate means for reducing the number of in …

Conclusions The pharmacokinetics of midazolam in our patients showed a shorter half-life,
probably due to the higher hepatic clearance based on the high CI in children, as …

Ozalin®, a novel oral solution of 0.2% midazolam, is an effective option for moderate
sedation prior to a therapeutic or diagnostic procedure, and as premedication before …

Background Children are in a continuous and dynamically changing state of growth and
development. A thorough understanding of developmental pharmacokinetics (PK) and …

Clinical implications of pharmacokinetics and pharmacodynami... : Current Opinion in Pediatrics
Clinical implications of pharmacokinetics and pharmacodynamics of procedural sedation agents …

Pediatric drug development faces many difficulties. Traditionally, pediatric drug doses are
simply calculated linearly based on the body weight, age, and body surface area of adults …

Abstract Background and Objective More than half of all drugs are still prescribed off-label to
children. Pharmacokinetic (PK) data are needed to support off-label dosing, however for …

To predict first‐pass and systemic cytochrome P450 (CYP) 3A‐mediated metabolism of
midazolam in preterm neonates, a physiological population pharmacokinetic model was …

Aims To create a general physiologically based pharmacokinetic (PBPK) model for drug
disposition in infants and children, covering the age range from birth to adulthood, and to …

Introduction Comparative pharmacokinetic (PK) data analysis of drugs administered using
developed child-appropriate and market authorized dosage formulation is sparse and is …